NCBI PubMed Central
open access
Semaglutide attenuates a proteomics-based dementia risk signature in older adults with overweight or obesity and cardiovascular disease without diabetes: A post hoc analysis of the SELECT phase 3 trial.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Improving Quality of Life in Older Patients With Frailty and Hematological Cancer Through Geriatric Assessment#1152652
- Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort#915494
- Galantamine Effects in Patients With Metabolic Syndrome#913652
- Feasibility, use and usability of an adapted mHealth tool for dementia risk reduction among middle-aged and older adults in Germany: protocol for a non-randomised pilot study.#988287
- Legacy neuropsychiatric benefit after semaglutide is linked to maximum achieved dose and independent of the maximum weight lost#216669
Record · ID 440727
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive